Key facts
- It has raised $3.3M across 2 recorded rounds; the latest was Seed Round ($3.3M) in Aug 2025.
- Notable investors include Springboard Enterprises, National Institutes of Health, Innosphere Ventures, CSU Starta, California Life Sciences — 9 tracked in total.
- SiVEC Biotechnologies has filed 1 Form D with the SEC, most recently Sep 2025 ($3.3M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for SiVEC Biotechnologies
Funding rounds
2 roundsAbout SiVEC Biotechnologies
Developer of a live biotherapeutic delivery platform designed to advance nucleic acid and gene therapies into clinical trials. The company's delivery system uses genetically engineered bacteria as shuttle vehicles for safe, tissue-targeted delivery of therapeutics, including small interfering ribonucleic acid, micro ribonucleic acids, clustered regularly interspaced short palindromic repeats, and proteins, allowing the nucleic acid and gene editing therapies, enabling physicians with technology to address several therapeutic needs.
- Industry
- Drug Delivery
- Sector
- Healthcare
- HQ
- Fort Collins, CO, United States
- Founded
- 2016
- Employees
- 5
- Website
- sivecbiotechnologies.com/
- Ownership
- Privately Held (backing)
SiVEC Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SiVEC Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SiVEC Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.